OBJECTIVE: To determine the short-term outcome of neuropsychiatric (NP) events upon enrollment into an international inception cohort of patients with systemic lupus erythematosus (SLE). METHODS: The study was performed by the Systemic Lupus International Collaborating Clinics. Patients were enrolled within 15 months of SLE diagnosis and NP events were characterized using the American College of Rheumatology case definitions. Decision rules were derived to identify NP events attributable to SLE. Physician outcome scores of NP events and patient-derived mental component summary (MCS) and physical component summary (PCS) scores of the Short Form 36 were recorded. RESULTS: There were 890 patients (88.7% female) with a mean +/- SD age of 33.8 +/- 13.4 years and mean disease duration of 5.3 +/- 4.2 months. Within the enrollment window, 271 (33.5%) of 890 patients had at least 1 NP event encompassing 15 NP syndromes. NP events attributed to SLE varied from 16.5% to 33.9% using alternate attribution models and occurred in 6.0-11.5% of patients. Outcome scores for NP events attributed to SLE were significantly better than for NP events due to non-SLE causes. Higher global disease activity was associated with worse outcomes. MCS scores were lower in patients with NP events, regardless of attribution, and were also lower in patients with diffuse and central NP events. There was a significant association between physician outcome scores and patient MCS scores only for NP events attributed to SLE. CONCLUSION: In SLE patients, the short-term outcome of NP events is determined by both the characteristics and attribution of the events.
OBJECTIVE: To determine the short-term outcome of neuropsychiatric (NP) events upon enrollment into an international inception cohort of patients with systemic lupus erythematosus (SLE). METHODS: The study was performed by the Systemic Lupus International Collaborating Clinics. Patients were enrolled within 15 months of SLE diagnosis and NP events were characterized using the American College of Rheumatology case definitions. Decision rules were derived to identify NP events attributable to SLE. Physician outcome scores of NP events and patient-derived mental component summary (MCS) and physical component summary (PCS) scores of the Short Form 36 were recorded. RESULTS: There were 890 patients (88.7% female) with a mean +/- SD age of 33.8 +/- 13.4 years and mean disease duration of 5.3 +/- 4.2 months. Within the enrollment window, 271 (33.5%) of 890 patients had at least 1 NP event encompassing 15 NP syndromes. NP events attributed to SLE varied from 16.5% to 33.9% using alternate attribution models and occurred in 6.0-11.5% of patients. Outcome scores for NP events attributed to SLE were significantly better than for NP events due to non-SLE causes. Higher global disease activity was associated with worse outcomes. MCS scores were lower in patients with NP events, regardless of attribution, and were also lower in patients with diffuse and central NP events. There was a significant association between physician outcome scores and patient MCS scores only for NP events attributed to SLE. CONCLUSION: In SLE patients, the short-term outcome of NP events is determined by both the characteristics and attribution of the events.
Authors: L Barile-Fabris; R Ariza-Andraca; L Olguín-Ortega; L J Jara; A Fraga-Mouret; J M Miranda-Limón; J Fuentes de la Mata; P Clark; F Vargas; J Alocer-Varela Journal: Ann Rheum Dis Date: 2005-04 Impact factor: 19.103
Authors: D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma Journal: Arthritis Rheum Date: 1996-03
Authors: Paola C Roldan; Rex E Jung; Wilmer L Sibbitt; Clifford R Qualls; Ranee A Flores; Carlos A Roldan Journal: Rheumatol Int Date: 2018-06-13 Impact factor: 2.631
Authors: J G Hanly; M B Urowitz; D Jackson; S C Bae; C Gordon; D J Wallace; A Clarke; S Bernatsky; A Vasudevan; D Isenberg; A Rahman; J Sanchez-Guerrero; J Romero-Diaz; J T Merrill; P R Fortin; D D Gladman; I N Bruce; K Steinsson; M Khamashta; G S Alarcón; B Fessler; M Petri; S Manzi; O Nived; G Sturfelt; R Ramsey-Goldman; M A Dooley; C Aranow; R Van Vollenhoven; M Ramos-Casals; A Zoma; K Kalunian; V Farewell Journal: Ann Rheum Dis Date: 2011-02-21 Impact factor: 19.103
Authors: Gail S Ross; Frank Zelko; Marisa Klein-Gitelman; Deborah M Levy; Eyal Muscal; Laura E Schanberg; Kelly Anthony; Hermine I Brunner Journal: Arthritis Care Res (Hoboken) Date: 2010-07 Impact factor: 4.794
Authors: Wilmer L Sibbitt; William M Brooks; Mario Kornfeld; Blaine L Hart; Arthur D Bankhurst; Carlos A Roldan Journal: Semin Arthritis Rheum Date: 2009-10-31 Impact factor: 5.532
Authors: J G Hanly; M B Urowitz; L Su; S C Bae; C Gordon; D J Wallace; A Clarke; S Bernatsky; D Isenberg; A Rahman; G S Alarcón; D D Gladman; P R Fortin; J Sanchez-Guerrero; J Romero-Diaz; J T Merrill; E Ginzler; I N Bruce; K Steinsson; M Khamashta; M Petri; S Manzi; M A Dooley; R Ramsey-Goldman; R Van Vollenhoven; O Nived; G Sturfelt; C Aranow; K Kalunian; M Ramos-Casals; A Zoma; J Douglas; K Thompson; V Farewell Journal: Ann Rheum Dis Date: 2009-04-08 Impact factor: 19.103